Based on classic clinicopathological variables, a significant proportion of estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer are categorized as clinically intermediate risk, thus providing limited information to guide adjuvant chemotherapy decisions. Here, ERBB2 is linked to breast cancer.